Stocktoria
AGENUS INC AGEN
AGENUS INC (AGEN) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| GLUE | Monte Rosa Therapeutics, Inc. | 4/9 | 1.67 | — | +63.5% |
| STRO | SUTRO BIOPHARMA, INC. | 2/9 | — | — | +65.2% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
About AGENUS INC
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
FAQ
Is AGEN financially healthy?
AGENUS INC's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does AGEN pay a dividend?
No, AGENUS INC does not currently pay a dividend.
What is the analyst price target for AGEN?
The average Wall-Street price target for AGENUS INC is $15.50, about 124.6% above the recent price, from 2 analysts (consensus: strong buy).
Is AGEN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AGENUS INC: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.